W
WAVEMAN · COMPANY
NAMS · Newamsterdam Pharma Co N.V.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

NAMS

NewAmsterdam Pharma Co N.V.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001936258
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$11.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
118
13F, latest reported quarter
REVENUE GROWTH
-50.6%
XBRL, annual
NET MARGIN
-905.7%
CONVERSIONS · 180D
7
codes C/M, not in net · $2.3M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$11.1M over 180 days
-$4.4M over 90 days
below 85% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
118 funds added or opened last quarter
more than 71% of Pharma & Biotech
REVENUE
-50.6% year over year
below 84% of Pharma & Biotech
MARGIN
-905.7% net margin
below 88% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
8.3% of shares outstanding short · 9.8 days to cover · settled 2026-07-31
more than 70% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$11.1M across 3 people in 180 days.
118 funds added or opened positions in the latest 13F quarter, of 199 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +5.0%
+5.0%12M
-2%+21%+45%+68%2025-092025-102025-122026-032026-052026-072026-09 2026-03-02 · Davidson Michael H. sold $14.8M2026-02-26 · Davidson Michael H. sold $5.6M2026-03-05 · Kastelein Johannes Jacob Pieter sold $3.2M2026-03-09 · Kastelein Johannes Jacob Pieter sold $3.1M2026-03-06 · Kastelein Johannes Jacob Pieter sold $2.9M2025-12-23 · Kooij Louise Frederika sold $2.7M2025-09-09 · Kooij Louise Frederika sold $2.5M2026-05-26 · Kooij Louise Frederika sold $2.3M2026-02-24 · Davidson Michael H. sold $2.2M2026-07-20 · Kooij Louise Frederika sold $2.1M2026-02-25 · Davidson Michael H. sold $1.6M2025-12-26 · Kooij Louise Frederika sold $1.5M2025-09-09 · Kooij Louise Frederika sold $1.3M2026-03-11 · LANGE LOUIS G sold $1.3M2026-01-27 · Kooij Louise Frederika sold $1.3M2026-01-20 · Somaiya Mayur Ian sold $1.3M2026-06-22 · Kooij Louise Frederika sold $1.2M2026-01-26 · Kooij Louise Frederika sold $1.1M2026-02-20 · Kastelein Johannes Jacob Pieter sold $1.1M2026-01-28 · Kooij Louise Frederika sold $1.0M2026-07-20 · Kooij Louise Frederika sold $990.0K2025-12-24 · Kooij Louise Frederika sold $928.1K2026-01-23 · Kooij Louise Frederika sold $849.5K2026-03-06 · LANGE LOUIS G sold $829.0K2026-01-21 · Somaiya Mayur Ian sold $823.4K2026-01-20 · Somaiya Mayur Ian sold $634.8K2026-02-26 · Davidson Michael H. sold $617.3K2026-02-20 · Kastelein Johannes Jacob Pieter sold $514.2K2026-01-21 · Somaiya Mayur Ian sold $512.8K2025-09-03 · Kooij Louise Frederika sold $453.5K2026-01-23 · Kooij Louise Frederika sold $438.8K2026-02-25 · Davidson Michael H. sold $375.3K2026-01-05 · Kastelein Johannes Jacob Pieter sold $199.5K2026-01-05 · Somaiya Mayur Ian sold $170.2K2026-02-24 · Davidson Michael H. sold $115.3K2026-07-20 · Kooij Louise Frederika sold $92.4K2026-01-05 · Kooij Louise Frederika sold $88.0K2026-02-25 · Davidson Michael H. sold $47.7K2025-09-08 · Topper James N bought $31.5K2026-01-20 · Somaiya Mayur Ian sold $27.6K2025-09-15 · Topper James N bought $15.6K2026-03-11 · LANGE LOUIS G sold $13.9K2026-08-24 · Kastelein Johannes Jacob Pieter filed to sell $3.5M
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $11.1M sold by insiders over 180 days, 118 funds added last quarter, $3.5M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, NewAmsterdam Pharma Co N.V. insiders sold a net $11.1M of stock across 112 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-07-20
70,200.0
$2.1M
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-07-20
31,885.0
$990.0K
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-07-20
2,915.0
$92.4K
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-06-22
300.0
$9.2K
Kooij Louise Frederika
Chief Accounting Officer
SELL
2026-06-22
39,700.0
$1.2M
112 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 107 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Frazier Life Sciences Management, L.P.
18,589,235.0 sh
$623.7M
Capital World Investors
12,230,557.0 sh
$414.5M
FMR LLC
10,339,663.0 sh
$350.4M
RA CAPITAL MANAGEMENT, L.P.
9,883,524.0 sh
$330.8M
FCPM III SERVICES B.V.
8,490,353.0 sh
$287.7M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Kastelein Johannes Jacob Pieter
FILED 2026-08-24
$3.5M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ALPS Medical Breakthroughs ETF
$3.6M POSITION · AS OF 2026-02-28
2.6%
AlphaCentric Life Sciences and Healthcare Fund
$469.1K POSITION · AS OF 2026-03-31
1.2%
Global X Guru Index ETF
$510.2K POSITION · AS OF 2026-04-30
0.9%
NORTH SQUARE KENNEDY MICROCAP FUND
$166.7K POSITION · AS OF 2026-02-28
0.6%
Empower Small Cap Growth Fund
$1.3M POSITION · AS OF 2026-03-31
0.6%
NICHOLAS PARTNERS SMALL CAP GROWTH FUND
$797.5K POSITION · AS OF 2026-03-31
0.5%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$13.6M
$30.5M
$4.3M
+222%
+35%
2024
$6.5M
$49.5M
$2.6M
+136%
+4%
2023
$5.8M
$4.7M
$3.3M
+2%
+5%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$22.5M$45.6M$14.1M$102.7M
OPERATING INCOME$-225.7M$-176.3M$-183.0M$-3.6M
NET INCOME$-203.0M$-242.0M$-177.0M$-22.6M
EPS (DILUTED)-1.72-2.56-2.15-1.19
OPERATING CASH FLOW$-147.8M$-158.6M$-141.2M$10.7M
CASH$490.0M$771.7M$340.4M—
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →